Shanghai Pharmaceuticals Holding Co., Ltd

Symbol: SHPMY

PNK

7.41

USD

Market price today

  • 51.8164

    P/E Ratio

  • 0.1005

    PEG Ratio

  • 7.20B

    MRK Cap

  • 0.01%

    DIV Yield

Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.11%

Operating Profit Margin

0.03%

Net Profit Margin

0.01%

Return on Assets

0.02%

Return on Equity

0.06%

Return on Capital Employed

0.08%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Distribution
CEO:Mr. Bo Shen
Full-time employees:47877
City:Shanghai
Address:Shanghai Pharmaceutical Building
IPO:2014-02-19
CIK:

Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People's Republic of China. It operates through four segments: Production, Distribution, Retail, and Others. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including oncology, cerebrocardiovascular, CNS, general infection, immunology, digestive and metabolism, and respiratory. It provides approximately 700 varieties of drugs. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores; online drug business; and provision of consulting services, assets management operations, as well as clinical trials, medical aid, physicians and patients' education, e-prescription management, and remote and cloud hospitals. Further, the company manufactures and trades in medicines. It operates approximately 2,000 retail chain pharmacies in 24 provinces. The company was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.

General Outlook

When we look at how much money they make before expenses, they keep 0.113% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.028%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.014%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.017% return, is a testament to Shanghai Pharmaceuticals Holding Co., Ltd's adeptness in optimizing resource deployment. Shanghai Pharmaceuticals Holding Co., Ltd's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.055%. Furthermore, the proficiency of Shanghai Pharmaceuticals Holding Co., Ltd in capital utilization is underscored by a remarkable 0.080% return on capital employed.

Stock Prices

Shanghai Pharmaceuticals Holding Co., Ltd's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $7.47, while its low point bottomed out at $7.18. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Shanghai Pharmaceuticals Holding Co., Ltd's stock market.

Liquidity Ratios

Analyzing SHPMY liquidity ratios reveals its financial health of the firm. The current ratio of 133.63% gauges short-term asset coverage for liabilities. The quick ratio (100.09%) assesses immediate liquidity, while the cash ratio (23.98%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio133.63%
Quick Ratio100.09%
Cash Ratio23.98%

Profitability Ratios

SHPMY profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 2.55% underscores its earnings before tax deductions. The effective tax rate stands at 28.20%, revealing its tax efficiency. The net income per EBT, 56.30%, and the EBT per EBIT, 91.41%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 2.79%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin2.55%
Effective Tax Rate28.20%
Net Income per EBT56.30%
EBT per EBIT91.41%
EBIT per Revenue2.79%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.34, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding100
Days of Inventory Outstanding64
Operating Cycle186.09
Days of Payables Outstanding80
Cash Conversion Cycle106
Receivables Turnover2.99
Payables Turnover4.58
Inventory Turnover5.70
Fixed Asset Turnover14.38
Asset Turnover1.21

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.75, and free cash flow per share, -0.10, depict cash generation on a per-share basis. The cash per share value, 10.04, showcases liquidity position. A payout ratio of 1.03 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.01, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share0.75
Free Cash Flow per Share-0.10
Cash per Share10.04
Payout Ratio1.03
Operating Cash Flow Sales Ratio0.01
Free Cash Flow to Operating Cash Flow Ratio-0.14
Cash Flow Coverage Ratio0.05
Short Term Coverage Ratio0.06
Capital Expenditure Coverage Ratio0.88
Dividend Paid and Capex Coverage Ratio0.39
Dividend Payout Ratio0.02

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 24.79%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.77, we discern the balance between debt and equity financing. The long-term debt to capitalization, 8.63%, and total debt to capitalization, 43.48%, ratios shed light on its capital structure. An interest coverage of 3.95 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio24.79%
Debt Equity Ratio0.77
Long Term Debt to Capitalization8.63%
Total Debt to Capitalization43.48%
Interest Coverage3.95
Cash Flow to Debt Ratio0.05
Company Equity Multiplier3.10

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 70.13, provides a glimpse into top-line earnings distributed across each share. Net income per share, 1.02, reflects the portion of profit attributed to each share. The book value per share, 18.51, represents the net asset value distributed per share, while the tangible book value per share, 17.06, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share70.13
Net Income Per Share1.02
Book Value Per Share18.51
Tangible Book Value Per Share17.06
Shareholders Equity Per Share18.51
Interest Debt Per Share15.91
Capex Per Share-0.80

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 11.89%, indicates top-line expansion, while the gross profit growth, -4.77%, reveals profitability trends. EBIT growth, -9.09%, and operating income growth, -9.09%, offer insights into operational profitability progression. The net income growth, -32.92%, showcases bottom-line expansion, and the EPS growth, -36.65%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth11.89%
Gross Profit Growth-4.77%
EBIT Growth-9.09%
Operating Income Growth-9.09%
Net Income Growth-32.92%
EPS Growth-36.65%
EPS Diluted Growth-36.65%
Weighted Average Shares Growth6.28%
Weighted Average Shares Diluted Growth6.28%
Dividends per Share Growth21.08%
Operating Cash Flow Growth31.01%
Free Cash Flow Growth57.57%
10-Year Revenue Growth per Share-51.79%
5-Year Revenue Growth per Share-75.02%
3-Year Revenue Growth per Share3.85%
10-Year Operating CF Growth per Share-7.24%
5-Year Operating CF Growth per Share-69.66%
3-Year Operating CF Growth per Share-30.29%
10-Year Net Income Growth per Share-75.59%
5-Year Net Income Growth per Share-85.14%
3-Year Net Income Growth per Share-35.65%
10-Year Shareholders Equity Growth per Share-61.64%
5-Year Shareholders Equity Growth per Share-73.11%
3-Year Shareholders Equity Growth per Share16.01%
10-Year Dividend per Share Growth per Share-45.19%
5-Year Dividend per Share Growth per Share-74.15%
3-Year Dividend per Share Growth per Share26.41%
Receivables Growth5.70%
Inventory Growth6.28%
Asset Growth6.98%
Book Value per Share Growth-3.85%
Debt Growth51.85%
R&D Expense Growth-5.37%
SGA Expenses Growth19.73%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 222,159,516,186.917, captures the company's total value, considering both debt and equity. Income quality, 1.65, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.02, gauges operational efficiency, while the research and development to revenue, 0.77%, highlights investment in innovation. The ratio of intangibles to total assets, 8.38%, indicates the value of non-physical assets, and capex to operating cash flow, -47.80%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value222,159,516,186.917
Income Quality1.65
Sales General and Administrative to Revenue0.02
Research and Development to Revenue0.77%
Intangibles to Total Assets8.38%
Capex to Operating Cash Flow-47.80%
Capex to Revenue-1.14%
Capex to Depreciation-125.81%
Graham Number20.59
Return on Tangible Assets1.94%
Graham Net Net-3.07
Working Capital40,061,983,314
Tangible Asset Value63,137,499,775
Net Current Asset Value31,353,506,156
Invested Capital1
Average Receivables78,818,869,729
Average Payables49,740,269,860.5
Average Inventory35,541,805,347.5
Days Sales Outstanding114
Days Payables Outstanding76
Days of Inventory On Hand58
ROIC4.75%
ROE0.05%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.80, and the price to book ratio, 2.80, reflect the market's valuation relative to the company's book value. The price to sales ratio, 0.20, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -140.09, and price to operating cash flows, 70.92, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio2.80
Price to Book Ratio2.80
Price to Sales Ratio0.20
Price Cash Flow Ratio70.92
Price Earnings to Growth Ratio0.10
Enterprise Value Multiple2.93
Price Fair Value2.80
Price to Operating Cash Flow Ratio70.92
Price to Free Cash Flows Ratio-140.09
Price to Tangible Book Ratio2.82
Enterprise Value to Sales0.86
Enterprise Value Over EBITDA21.05
EV to Operating Cash Flow35.75
Earnings Yield1.95%
Free Cash Flow Yield1.68%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) on the PNK in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 51.816 in 2024.

What is the ticker symbol of Shanghai Pharmaceuticals Holding Co., Ltd stock?

The ticker symbol of Shanghai Pharmaceuticals Holding Co., Ltd stock is SHPMY.

What is company IPO date?

IPO date of Shanghai Pharmaceuticals Holding Co., Ltd is 2014-02-19.

What is company current share price?

Current share price is 7.410 USD.

What is stock market cap today?

The market cap of stock today is 7202919295.000.

What is PEG ratio in 2024?

The current 0.100 is 0.100 in 2024.

What is the number of employees in 2024?

In 2024 the company has 47877.